Exosomal MicroRNA Analyses in Esophageal Squamous Cell Carcinoma Cell Lines.
biomarker
esophageal squamous cell carcinoma
exosome
microRNA
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
13
06
2022
revised:
23
07
2022
accepted:
26
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Exosomal miRNAs have been studied in various cancers as minimally invasive biomarkers. This study aimed to investigate the potential of exosomal microRNAs (miRNAs) as biomarkers for esophageal squamous cell carcinoma (ESCC). Exosomes were isolated from cultures of esophageal epithelial cell and ESCC cell lines using ExoDisc, and exosomal miRNAs were detected via miRNA sequencing. Of the differentially expressed 14 miRNAs, the top 2 up-regulated miRNAs (miR-205-5p and miR-429) and top 2 down-regulated miRNAs (miR-375-3p and miR-483-3p) were selected as ESCC target miRNAs. Four selected exosomal miRNAs were validated in the plasma of 20 healthy controls (HCs) and 40 ESCC patients via quantitative reverse transcription-polymerase chain reaction. The expression of plasma exosomal miR-205-5p and miR-429 significantly increased, while that of plasma exosomal miR-375-3p was significantly reduced in ESCC patients compared to that in HCs. At cut-off values of 5.04, 2.564, and 0.136, the sensitivity and specificity for the diagnosis of ESCC were 72.5% and 70.0% for miR-205-5p, 60.0% and 60.0% for miR-429, and 65.0% and 65.0% for miR-375-3p, respectively. Based on the exosomal miRNAs identified in ESCC cell lines, our study demonstrated that plasma exosomal miR-205-5p, miR-429, and miR-375-3p could serve as potential biomarkers for ESCC diagnosis.
Identifiants
pubmed: 35956043
pii: jcm11154426
doi: 10.3390/jcm11154426
pmc: PMC9369365
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Foundation of Korea (NRF) grant funded by the Korea government
ID : 2019R1F1A1061975
Références
Int J Cancer. 2014 Sep 1;135(5):1011-8
pubmed: 24166096
Sci Rep. 2020 Aug 11;10(1):13572
pubmed: 32782317
Int J Oncol. 2018 Mar;52(3):841-850
pubmed: 29393341
Oncol Rep. 2019 Dec;42(6):2528-2536
pubmed: 31638236
BMC Genomics. 2013 May 10;14:319
pubmed: 23663360
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
J Cancer. 2020 Jul 9;11(18):5329-5344
pubmed: 32742479
Mol Cell Biochem. 2013 Nov;383(1-2):67-75
pubmed: 23881177
J Cancer. 2018 Jan 1;9(2):407-414
pubmed: 29344287
Nat Genet. 2014 May;46(5):467-73
pubmed: 24686850
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Gut. 2012 Jan;61(1):33-42
pubmed: 21813472
Diagnostics (Basel). 2021 Jul 31;11(8):
pubmed: 34441325
Am J Cancer Res. 2017 Feb 01;7(2):218-233
pubmed: 28337372
Front Pharmacol. 2020 Jan 20;10:1500
pubmed: 32038230
Front Genet. 2019 Jul 18;10:626
pubmed: 31379918
J Pathol Transl Med. 2020 May;54(3):204-212
pubmed: 32460474
Cancer Manag Res. 2014 Apr 25;6:205-16
pubmed: 24812525
Proteomics. 2005 Jul;5(11):2960-71
pubmed: 15986332
Int J Mol Sci. 2013 Jul 09;14(7):14240-69
pubmed: 23839094
Semin Radiat Oncol. 2007 Jan;17(1):2-9
pubmed: 17185192
Dis Esophagus. 2012 Apr;25(3):242-9
pubmed: 21895853
Sci Rep. 2017 Feb 01;7:41330
pubmed: 28145479
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Cancer. 2011 Nov 24;11(12):849-64
pubmed: 22113163
Future Sci OA. 2020 Feb 26;6(4):FSO465
pubmed: 32257377
J Gastroenterol Hepatol. 2019 Mar;34(3):552-560
pubmed: 30426559
Chembiochem. 2019 Feb 15;20(4):451-461
pubmed: 30371016
Gastrointest Endosc. 2018 Sep;88(3):413-426
pubmed: 29709526
PLoS One. 2020 Apr 6;15(4):e0231116
pubmed: 32251457
Int J Mol Sci. 2014 Sep 02;15(9):15530-51
pubmed: 25184951
Chonnam Med J. 2015 Aug;51(2):51-7
pubmed: 26306299
World J Gastroenterol. 2012 Oct 14;18(38):5442-53
pubmed: 23082062
Biomed Res Int. 2014;2014:864894
pubmed: 24963487
Cancer Res. 2009 Mar 15;69(6):2287-95
pubmed: 19244118
Pathol Res Pract. 2019 Sep;215(9):152526
pubmed: 31324391
Br J Cancer. 2011 Jun 28;105(1):104-11
pubmed: 21673684
Mol Carcinog. 2011 Feb;50(2):136-42
pubmed: 21229610
Genomics Proteomics Bioinformatics. 2015 Feb;13(1):17-24
pubmed: 25724326
Onco Targets Ther. 2016 Mar 03;9:1123-33
pubmed: 27042104
Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1202-1210
pubmed: 32096149
Int J Mol Sci. 2019 Aug 09;20(16):
pubmed: 31395836
Int J Oncol. 2015 Feb;46(2):539-47
pubmed: 25384963